fluasterone (HE2500) / Aeson Therap - LARVOL DELTA

The glucocorticoid antagonist ST001 prevents development of NASH and improves aspects of the metabolic syndrome in the DIAMOND(tm) mouse model (EASL-ILC 2019) - "Fluasterone successfully met the primary study end point of preventing NASH development. While not an insulin sensitizer, it did improve some measures of insulin sensitivity and metabolic syndrome, suggesting that the development of NASH in this model may be partly driven by glucocorticoids as with Cushing™s disease. These results support the biological rationale for further testing of anti-glucocorticoid compounds with immunosuppressive effects like fluasterone as NASH therapeutics.Figure:"

Preclinical